市場調査レポート

商品コード

1454048

慢性咳嗽市場の2030年までの予測：薬剤クラス別、投与経路別、流通チャネル別、エンドユーザー別、地域別の世界分析

Chronic Cough Market Forecasts to 2030 - Global Analysis By Drug Class, Route of Administration, Distribution Channel, End User and By Geography

出版日: 2024年03月03日 | 発行: Stratistics Market Research Consulting

| ページ情報: 英文 200+ Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF (Single User License)

USD 4,150 652,131円

レポートPDFを1名様のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は1回のみ可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (2-5 User License)

USD 5,250 824,985円

レポートPDFを同一事業所（所在地）内の5名までご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は5回まで可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF & Excel (Site License)

USD 6,350 997,839円

レポートPDFおよびExcelを同一事業所（所在地）内のすべての方にご利用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は5回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

PDF & Excel (Global Site License)

USD 7,500 1,178,550円

レポートPDFおよびExcelを企業内すべての方に使用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は10回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=157.14円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

Stratistics MRCによると、世界の慢性咳嗽市場は2023年に73億米ドルを占め、予測期間中にCAGR 10.0％で成長し、2030年には143億米ドルに達する見込みです。

慢性咳嗽とは、ほとんどの医学的定義によれば、成人で8週間以上、小児で4週間以上続く持続的な咳のことです。慢性咳嗽は、疾患そのものというよりはむしろ症状であり、喘息、アレルギー、胃食道逆流症（GERD）、鼻汁後、喫煙、慢性気管支炎、特定の薬剤など、さまざまな基礎疾患によって引き起こされる可能性があります。慢性の咳は、生活の質に大きな影響を与える可能性があり、根本的な原因と適切な治療を決定するために医学的評価が必要となる場合があります。

インドの国家保健政策2017によると、慢性咳嗽を含む非伝染性疾患による早期死亡率を2025年までに25％削減するとしています。

慢性呼吸器疾患の増加

市場は、慢性呼吸器疾患の有病率の顕著な上昇を目の当たりにしています。この急増は、環境汚染、ライフスタイルの変化、高齢化などさまざまな要因に起因しています。慢性呼吸器疾患はますます蔓延しており、市場の拡大に寄与しています。意識の高まりと診断の進歩に伴い、慢性呼吸器疾患に対する効果的な治療法に対する需要は増加の一途をたどっており、この分野のさらなる成長の原動力となっています。

副作用と安全性への懸念

慢性咳嗽治療薬の一般的な副作用には、眠気、めまい、胃腸障害などがあります。薬物相互作用の可能性や、特定の薬物による依存や乱用のリスクに関する安全性への懸念もあります。心血管疾患や呼吸器疾患などの基礎疾患を有する患者は、リスクが高まる可能性があります。ヘルスケアプロバイダーは、これらの懸念を軽減するために、各患者の病歴を注意深く評価し、治療結果を注意深くモニターすることが不可欠です。したがって、これらが市場の成長を阻害する要因となっています。

ヘルスケア支出の増加

同市場では、診断率の上昇、患者数の拡大、治療法の進歩などさまざまな要因によって、ヘルスケア支出が顕著に増加しています。意識が高まり、慢性咳嗽の治療を求める患者が増えるにつれて、医療費は着実に増加し続けています。この動向は、慢性咳嗽をヘルスケアの優先課題として取り組むことの重要性を強調し、この市場セグメントにおける研究開発および患者ケアの取り組みへの継続的な投資の必要性を浮き彫りにしています。

高額な治療費

慢性咳嗽市場は治療費の高騰という大きな課題に取り組んでおり、患者にもヘルスケアシステムにも大きな負担を強いています。治療と継続的な管理に伴う費用は、この持続的な症状からの解放を求める患者にとって経済的負担の一因となっています。医療技術や治療方法の進歩にもかかわらず、高額な治療費は依然として多くの患者にとって治療の障壁となっており、ヘルスケアにおいて手頃な価格で持続可能な解決策が急務となっています。

COVID-19の影響：

COVID-19の大流行は慢性咳嗽市場に大きな影響を与え、診断、治療、患者ケアに混乱をもたらしました。封鎖措置、ヘルスケアへのアクセスの減少、COVID-19の管理にリソースを優先させたことが、慢性咳嗽の管理の遅れにつながった。さらに、ヘルスケア施設を訪れることへの恐怖が、患者が適時に治療を受けることを躊躇させました。その結果、診断率や治療開始率が低下し、市場の成長に影響を与えました。遠隔医療が優先される診察方法として台頭し、制限のある中である程度の緩和をもたらしたが、対面での評価を完全に補うことはできなかった。

予測期間中、充血除去薬分野が最大となる見込み

呼吸器疾患に対する認識と有病率の高まりにより、鼻づまり緩和薬分野は予測期間中最大となる見込みです。鼻づまりや点鼻後の鼻水を緩和し、しつこい咳の根本的な原因に対処します。製薬会社は、既存の製剤を強化し、新規の鼻づまり除去剤を発売するため、研究開発に積極的に取り組んでいます。このダイナミックな市場情勢は、慢性的な咳や関連する呼吸器疾患の管理における効果的な充血除去薬の重要性を裏付けています。

予測期間中にCAGRが最も高くなると予想されるのは病院分野です。

予測期間中、CAGRが最も高くなると予想されるのは病院分野です。有名な学術医療センターや呼吸器科など、呼吸器の健康を専門とする大手病院が重要なプレーヤーです。これらの病院は、画像診断、肺機能検査、集学的な専門家チームへのアクセスなど、包括的なサービスを提供しています。さらに、最先端の治療法や臨床試験を提供し、患者が慢性的な咳の症状に対して最適なケアと管理を受けられるようにしています。

最大のシェアを占める地域

予測期間中、北米が最大の市場シェアを占めると予測されます。鎮咳薬や標的療法を含む薬物療法が市場を独占しています。さらに、新規治療法を目指した研究開発活動の急増が市場拡大をさらに後押ししています。患者の転帰と生活の質の向上に焦点を当て、市場は革新と投資の有望な機会とともに進化を続けています。

CAGRが最も高い地域：

アジア太平洋地域は、汚染レベルの上昇、高齢者人口の増加、呼吸器疾患の罹患率上昇につながるライフスタイルの変化、利用可能な治療オプションに関する意識の高まりにより、予測期間中に最も高いCAGRを維持すると予測されます。さらに、言語療法、呼吸訓練、生活習慣の改善といった非薬物学的介入への関心も高まっています。市場を管理する規制の枠組みは地域内の国によって異なり、市場力学と製品の入手可能性に影響を及ぼしています。

無料のカスタマイズサービス：

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

企業プロファイル
- 追加市場プレイヤーの包括的プロファイリング（3社まで）
- 主要企業のSWOT分析（3社まで）
地域セグメンテーション
- 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
競合ベンチマーキング
- 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

北米
- 米国
- カナダ
- メキシコ
欧州
- ドイツ
- 英国
- イタリア
- フランス
- スペイン
- その他欧州
アジア太平洋地域
- 日本
- 中国
- インド
- オーストラリア
- ニュージーランド
- 韓国
- その他アジア太平洋地域
南米
- アルゼンチン
- ブラジル
- チリ
- その他南米
中東とアフリカ
- サウジアラビア
- アラブ首長国連邦
- カタール
- 南アフリカ
- その他中東とアフリカ

第10章主な発展

契約、パートナーシップ、コラボレーション、合弁事業
買収と合併
新製品の発売
事業拡大
その他の主要戦略

第11章企業プロファイル

Teva Pharmaceuticals Industries
Mylan N.V.
Amneal Pharmaceuticals LLC
Novartis AG
Hikma Pharmaceuticals Plc
Bayer AG
GSK plc
Aurobindo Pharma
Apotex Inc.
Micro Labs Ltd
AstraZeneca plc
Sun Pharmaceuticals Industries Ltd
Cipla Limited
Glenmark Pharmaceuticals Ltd
NeRRe Therapeutics
Pfizer Inc.

図表

List of Tables

Table 1 Global Chronic Cough Market Outlook, By Region (2021-2030) ($MN)
Table 2 Global Chronic Cough Market Outlook, By Drug Class (2021-2030) ($MN)
Table 3 Global Chronic Cough Market Outlook, By Antibiotics (2021-2030) ($MN)
Table 4 Global Chronic Cough Market Outlook, By Acid Blockers (2021-2030) ($MN)
Table 5 Global Chronic Cough Market Outlook, By Corticosteroids (2021-2030) ($MN)
Table 6 Global Chronic Cough Market Outlook, By Decongestants (2021-2030) ($MN)
Table 7 Global Chronic Cough Market Outlook, By Combination Drug (2021-2030) ($MN)
Table 8 Global Chronic Cough Market Outlook, By Antihistamines (2021-2030) ($MN)
Table 9 Global Chronic Cough Market Outlook, By Other Drug Classes (2021-2030) ($MN)
Table 10 Global Chronic Cough Market Outlook, By Route of Administration (2021-2030) ($MN)
Table 11 Global Chronic Cough Market Outlook, By Inhalational (2021-2030) ($MN)
Table 12 Global Chronic Cough Market Outlook, By Oral (2021-2030) ($MN)
Table 13 Global Chronic Cough Market Outlook, By Injectable (2021-2030) ($MN)
Table 14 Global Chronic Cough Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
Table 15 Global Chronic Cough Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 16 Global Chronic Cough Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
Table 17 Global Chronic Cough Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
Table 18 Global Chronic Cough Market Outlook, By Online Pharmacy (2021-2030) ($MN)
Table 19 Global Chronic Cough Market Outlook, By End User (2021-2030) ($MN)
Table 20 Global Chronic Cough Market Outlook, By Speciality Centres (2021-2030) ($MN)
Table 21 Global Chronic Cough Market Outlook, By Homecare (2021-2030) ($MN)
Table 22 Global Chronic Cough Market Outlook, By Hospitals (2021-2030) ($MN)
Table 23 Global Chronic Cough Market Outlook, By Other End Users (2021-2030) ($MN)
Table 24 North America Chronic Cough Market Outlook, By Country (2021-2030) ($MN)
Table 25 North America Chronic Cough Market Outlook, By Drug Class (2021-2030) ($MN)
Table 26 North America Chronic Cough Market Outlook, By Antibiotics (2021-2030) ($MN)
Table 27 North America Chronic Cough Market Outlook, By Acid Blockers (2021-2030) ($MN)
Table 28 North America Chronic Cough Market Outlook, By Corticosteroids (2021-2030) ($MN)
Table 29 North America Chronic Cough Market Outlook, By Decongestants (2021-2030) ($MN)
Table 30 North America Chronic Cough Market Outlook, By Combination Drug (2021-2030) ($MN)
Table 31 North America Chronic Cough Market Outlook, By Antihistamines (2021-2030) ($MN)
Table 32 North America Chronic Cough Market Outlook, By Other Drug Classes (2021-2030) ($MN)
Table 33 North America Chronic Cough Market Outlook, By Route of Administration (2021-2030) ($MN)
Table 34 North America Chronic Cough Market Outlook, By Inhalational (2021-2030) ($MN)
Table 35 North America Chronic Cough Market Outlook, By Oral (2021-2030) ($MN)
Table 36 North America Chronic Cough Market Outlook, By Injectable (2021-2030) ($MN)
Table 37 North America Chronic Cough Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
Table 38 North America Chronic Cough Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 39 North America Chronic Cough Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
Table 40 North America Chronic Cough Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
Table 41 North America Chronic Cough Market Outlook, By Online Pharmacy (2021-2030) ($MN)
Table 42 North America Chronic Cough Market Outlook, By End User (2021-2030) ($MN)
Table 43 North America Chronic Cough Market Outlook, By Speciality Centres (2021-2030) ($MN)
Table 44 North America Chronic Cough Market Outlook, By Homecare (2021-2030) ($MN)
Table 45 North America Chronic Cough Market Outlook, By Hospitals (2021-2030) ($MN)
Table 46 North America Chronic Cough Market Outlook, By Other End Users (2021-2030) ($MN)
Table 47 Europe Chronic Cough Market Outlook, By Country (2021-2030) ($MN)
Table 48 Europe Chronic Cough Market Outlook, By Drug Class (2021-2030) ($MN)
Table 49 Europe Chronic Cough Market Outlook, By Antibiotics (2021-2030) ($MN)
Table 50 Europe Chronic Cough Market Outlook, By Acid Blockers (2021-2030) ($MN)
Table 51 Europe Chronic Cough Market Outlook, By Corticosteroids (2021-2030) ($MN)
Table 52 Europe Chronic Cough Market Outlook, By Decongestants (2021-2030) ($MN)
Table 53 Europe Chronic Cough Market Outlook, By Combination Drug (2021-2030) ($MN)
Table 54 Europe Chronic Cough Market Outlook, By Antihistamines (2021-2030) ($MN)
Table 55 Europe Chronic Cough Market Outlook, By Other Drug Classes (2021-2030) ($MN)
Table 56 Europe Chronic Cough Market Outlook, By Route of Administration (2021-2030) ($MN)
Table 57 Europe Chronic Cough Market Outlook, By Inhalational (2021-2030) ($MN)
Table 58 Europe Chronic Cough Market Outlook, By Oral (2021-2030) ($MN)
Table 59 Europe Chronic Cough Market Outlook, By Injectable (2021-2030) ($MN)
Table 60 Europe Chronic Cough Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
Table 61 Europe Chronic Cough Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 62 Europe Chronic Cough Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
Table 63 Europe Chronic Cough Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
Table 64 Europe Chronic Cough Market Outlook, By Online Pharmacy (2021-2030) ($MN)
Table 65 Europe Chronic Cough Market Outlook, By End User (2021-2030) ($MN)
Table 66 Europe Chronic Cough Market Outlook, By Speciality Centres (2021-2030) ($MN)
Table 67 Europe Chronic Cough Market Outlook, By Homecare (2021-2030) ($MN)
Table 68 Europe Chronic Cough Market Outlook, By Hospitals (2021-2030) ($MN)
Table 69 Europe Chronic Cough Market Outlook, By Other End Users (2021-2030) ($MN)
Table 70 Asia Pacific Chronic Cough Market Outlook, By Country (2021-2030) ($MN)
Table 71 Asia Pacific Chronic Cough Market Outlook, By Drug Class (2021-2030) ($MN)
Table 72 Asia Pacific Chronic Cough Market Outlook, By Antibiotics (2021-2030) ($MN)
Table 73 Asia Pacific Chronic Cough Market Outlook, By Acid Blockers (2021-2030) ($MN)
Table 74 Asia Pacific Chronic Cough Market Outlook, By Corticosteroids (2021-2030) ($MN)
Table 75 Asia Pacific Chronic Cough Market Outlook, By Decongestants (2021-2030) ($MN)
Table 76 Asia Pacific Chronic Cough Market Outlook, By Combination Drug (2021-2030) ($MN)
Table 77 Asia Pacific Chronic Cough Market Outlook, By Antihistamines (2021-2030) ($MN)
Table 78 Asia Pacific Chronic Cough Market Outlook, By Other Drug Classes (2021-2030) ($MN)
Table 79 Asia Pacific Chronic Cough Market Outlook, By Route of Administration (2021-2030) ($MN)
Table 80 Asia Pacific Chronic Cough Market Outlook, By Inhalational (2021-2030) ($MN)
Table 81 Asia Pacific Chronic Cough Market Outlook, By Oral (2021-2030) ($MN)
Table 82 Asia Pacific Chronic Cough Market Outlook, By Injectable (2021-2030) ($MN)
Table 83 Asia Pacific Chronic Cough Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
Table 84 Asia Pacific Chronic Cough Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 85 Asia Pacific Chronic Cough Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
Table 86 Asia Pacific Chronic Cough Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
Table 87 Asia Pacific Chronic Cough Market Outlook, By Online Pharmacy (2021-2030) ($MN)
Table 88 Asia Pacific Chronic Cough Market Outlook, By End User (2021-2030) ($MN)
Table 89 Asia Pacific Chronic Cough Market Outlook, By Speciality Centres (2021-2030) ($MN)
Table 90 Asia Pacific Chronic Cough Market Outlook, By Homecare (2021-2030) ($MN)
Table 91 Asia Pacific Chronic Cough Market Outlook, By Hospitals (2021-2030) ($MN)
Table 92 Asia Pacific Chronic Cough Market Outlook, By Other End Users (2021-2030) ($MN)
Table 93 South America Chronic Cough Market Outlook, By Country (2021-2030) ($MN)
Table 94 South America Chronic Cough Market Outlook, By Drug Class (2021-2030) ($MN)
Table 95 South America Chronic Cough Market Outlook, By Antibiotics (2021-2030) ($MN)
Table 96 South America Chronic Cough Market Outlook, By Acid Blockers (2021-2030) ($MN)
Table 97 South America Chronic Cough Market Outlook, By Corticosteroids (2021-2030) ($MN)
Table 98 South America Chronic Cough Market Outlook, By Decongestants (2021-2030) ($MN)
Table 99 South America Chronic Cough Market Outlook, By Combination Drug (2021-2030) ($MN)
Table 100 South America Chronic Cough Market Outlook, By Antihistamines (2021-2030) ($MN)
Table 101 South America Chronic Cough Market Outlook, By Other Drug Classes (2021-2030) ($MN)
Table 102 South America Chronic Cough Market Outlook, By Route of Administration (2021-2030) ($MN)
Table 103 South America Chronic Cough Market Outlook, By Inhalational (2021-2030) ($MN)
Table 104 South America Chronic Cough Market Outlook, By Oral (2021-2030) ($MN)
Table 105 South America Chronic Cough Market Outlook, By Injectable (2021-2030) ($MN)
Table 106 South America Chronic Cough Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
Table 107 South America Chronic Cough Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 108 South America Chronic Cough Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
Table 109 South America Chronic Cough Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
Table 110 South America Chronic Cough Market Outlook, By Online Pharmacy (2021-2030) ($MN)
Table 111 South America Chronic Cough Market Outlook, By End User (2021-2030) ($MN)
Table 112 South America Chronic Cough Market Outlook, By Speciality Centres (2021-2030) ($MN)
Table 113 South America Chronic Cough Market Outlook, By Homecare (2021-2030) ($MN)
Table 114 South America Chronic Cough Market Outlook, By Hospitals (2021-2030) ($MN)
Table 115 South America Chronic Cough Market Outlook, By Other End Users (2021-2030) ($MN)
Table 116 Middle East & Africa Chronic Cough Market Outlook, By Country (2021-2030) ($MN)
Table 117 Middle East & Africa Chronic Cough Market Outlook, By Drug Class (2021-2030) ($MN)
Table 118 Middle East & Africa Chronic Cough Market Outlook, By Antibiotics (2021-2030) ($MN)
Table 119 Middle East & Africa Chronic Cough Market Outlook, By Acid Blockers (2021-2030) ($MN)
Table 120 Middle East & Africa Chronic Cough Market Outlook, By Corticosteroids (2021-2030) ($MN)
Table 121 Middle East & Africa Chronic Cough Market Outlook, By Decongestants (2021-2030) ($MN)
Table 122 Middle East & Africa Chronic Cough Market Outlook, By Combination Drug (2021-2030) ($MN)
Table 123 Middle East & Africa Chronic Cough Market Outlook, By Antihistamines (2021-2030) ($MN)
Table 124 Middle East & Africa Chronic Cough Market Outlook, By Other Drug Classes (2021-2030) ($MN)
Table 125 Middle East & Africa Chronic Cough Market Outlook, By Route of Administration (2021-2030) ($MN)
Table 126 Middle East & Africa Chronic Cough Market Outlook, By Inhalational (2021-2030) ($MN)
Table 127 Middle East & Africa Chronic Cough Market Outlook, By Oral (2021-2030) ($MN)
Table 128 Middle East & Africa Chronic Cough Market Outlook, By Injectable (2021-2030) ($MN)
Table 129 Middle East & Africa Chronic Cough Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
Table 130 Middle East & Africa Chronic Cough Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 131 Middle East & Africa Chronic Cough Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
Table 132 Middle East & Africa Chronic Cough Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
Table 133 Middle East & Africa Chronic Cough Market Outlook, By Online Pharmacy (2021-2030) ($MN)
Table 134 Middle East & Africa Chronic Cough Market Outlook, By End User (2021-2030) ($MN)
Table 135 Middle East & Africa Chronic Cough Market Outlook, By Speciality Centres (2021-2030) ($MN)
Table 136 Middle East & Africa Chronic Cough Market Outlook, By Homecare (2021-2030) ($MN)
Table 137 Middle East & Africa Chronic Cough Market Outlook, By Hospitals (2021-2030) ($MN)
Table 138 Middle East & Africa Chronic Cough Market Outlook, By Other End Users (2021-2030) ($MN)

Product Code: SMRC25600

According to Stratistics MRC, the Global Chronic Cough Market is accounted for $7.3 billion in 2023 and is expected to reach $14.3 billion by 2030 growing at a CAGR of 10.0% during the forecast period. A chronic cough is a persistent cough that lasts for more than eight weeks in adults or four weeks in children, according to most medical definitions. It's a symptom rather than a disease itself and can be caused by a variety of underlying conditions such as asthma, allergies, gastroesophageal reflux disease (GERD), postnasal drip, smoking, chronic bronchitis, or certain medications. Chronic cough can significantly impact quality of life and may require medical evaluation to determine the underlying cause and appropriate treatment.

According to the National Health Policy 2017, India, premature mortality due to non-communicable diseases, including chronic cough, will be reduced by ~ 25% by 2025.

Market Dynamics:

Driver:

Increasing prevalence of chronic respiratory diseases

The market is witnessing a notable rise in chronic respiratory diseases prevalence. This surge is attributed to various factors such as environmental pollution, lifestyle changes, and aging populations. Chronic respiratory conditions are increasingly prevalent, contributing to the expansion of the market. With growing awareness and diagnostic advancements, the demand for effective treatments for chronic respiratory ailments continues to escalate, driving further growth in this sector.

Restraint:

Side effects and safety concerns

Common side effects of pharmaceutical treatments for chronic cough include drowsiness, dizziness, and gastrointestinal disturbances. There are safety concerns regarding potential drug interactions and the risk of dependency or abuse with certain medications. Patients with underlying medical conditions such as cardiovascular issues or respiratory disorders may face heightened risks. It's imperative for healthcare providers to carefully assess each patient's medical history and closely monitor treatment outcomes to mitigate these concerns. Hence, these are the factors impeding the growth of the market.

Opportunity:

Rising healthcare expenditure

The market is witnessing a notable surge in healthcare expenditure, driven by various factors such as increased diagnosis rates, expanding patient populations, and advancements in treatment options. As awareness grows and more patients seek medical attention for chronic cough, healthcare spending continues to rise steadily. This trend underscores the significance of addressing chronic cough as a healthcare priority and highlights the need for continued investment in research, development, and patient care initiatives within this market segment.

Threat:

High cost of treatment

The market grapples with the significant challenge of high treatment costs, posing a considerable burden on patients and healthcare systems alike. The expenses associated with therapies and ongoing management contribute to financial strain for individuals seeking relief from this persistent condition. Despite advancements in medical technology and treatment modalities, the steep costs remain a barrier to access for many, underscoring the pressing need for affordable and sustainable solutions within the healthcare landscape.

Covid-19 Impact:

The COVID-19 pandemic significantly affected the Chronic Cough market, causing disruptions in diagnosis, treatment, and patient care. Lockdown measures, reduced healthcare access, and prioritization of resources towards managing COVID-19 led to delays in chronic cough management. Additionally, fear of visiting healthcare facilities deterred patients from seeking timely treatment. Consequently, there was a decline in diagnosis rates and treatment initiation, impacting market growth. Telemedicine emerged as a preferred mode for consultation, offering some relief amidst restrictions but couldn't fully compensate for in-person evaluations.

The decongestants segment is expected to be the largest during the forecast period

The decongestants segment is expected to be the largest during the forecast period driven by increasing awareness and prevalence of respiratory conditions. They alleviate nasal congestion and postnasal drip, addressing underlying causes of persistent coughing. Pharmaceutical companies actively engage in research and development to enhance existing formulations and introduce novel decongestant products. This dynamic market landscape underscores the importance of effective decongestants in managing chronic cough and related respiratory ailments.

The hospitals segment is expected to have the highest CAGR during the forecast period

The hospitals segment is expected to have the highest CAGR during the forecast period. Leading hospitals specializing in respiratory health, such as renowned academic medical centers and pulmonology departments, are crucial players. These hospitals offer comprehensive services, including diagnostic imaging, pulmonary function testing, and access to multidisciplinary teams of specialists. Additionally, they provide cutting-edge therapies and clinical trials, ensuring patients receive optimal care and management for their chronic cough conditions.

Region with largest share:

North America is projected to hold the largest market share during the forecast period. Pharmaceutical interventions, including antitussive medications and targeted therapies, dominate the market landscape. Additionally, a surge in research and development activities aimed at novel treatment modalities further propels market expansion. With a focus on improving patient outcomes and quality of life, the market continues to evolve with promising opportunities for innovation and investment.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period owing to increasing pollution levels, rising geriatric population, changing lifestyles leading to higher incidence of respiratory diseases, and growing awareness about available treatment options. Additionally, there was growing interest in non-pharmacological interventions such as speech therapy, breathing exercises, and lifestyle modifications. Regulatory frameworks governing the market varied across countries in the region, influencing market dynamics and product availability.

Key players in the market

Some of the key players in Chronic Cough market include Teva Pharmaceuticals Industries, Mylan N.V., Amneal Pharmaceuticals LLC, Novartis AG, Hikma Pharmaceuticals Plc, Bayer AG, GSK plc, Aurobindo Pharma, Apotex Inc., Micro Labs Ltd, AstraZeneca plc, Sun Pharmaceuticals Industries Ltd, Cipla Limited, Glenmark Pharmaceuticals Ltd, NeRRe Therapeutics and Pfizer Inc.

Key Developments:

In September 2022, Pfizer Inc., a US-based biopharmaceutical company, acquired ASX-listed digital health startup ResApp Health for $115 million. With this acquisition, Pfizer aimed to enhance its product portfolio and expand its presence in crucial healthcare technology areas.

In January 2022, Merck announced Gefapixant, a non-narcotic, oral selective P2X3 receptor antagonist for the treatment of patients with RCC or unexplained chronic cough (UCC), was approved by FDA.

Drug Classes Covered:

Antibiotics
Acid Blockers
Corticosteroids
Decongestants
Combination Drug
Antihistamines
Other Drug Classes

Route of Administrations Covered:

Inhalational
Oral
Injectable
Other Route of Administrations

Distribution Channels Covered:

Retail Pharmacy
Hospital Pharmacy
Online Pharmacy

End Users Covered:

Speciality Centres
Homecare
Hospitals
Other End Users

Regions Covered:

North America
- US
- Canada
- Mexico
Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
South America
- Argentina
- Brazil
- Chile
- Rest of South America
Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa

What our report offers:

Market share assessments for the regional and country-level segments
Strategic recommendations for the new entrants
Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
Strategic recommendations in key business segments based on the market estimations
Competitive landscaping mapping the key common trends
Company profiling with detailed strategies, financials, and recent developments
Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

1 Executive Summary

2 Preface

2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions

3 Market Trend Analysis

3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 End User Analysis
3.7 Emerging Markets
3.8 Impact of Covid-19

4 Porters Five Force Analysis

4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Chronic Cough Market, By Drug Class

5.1 Introduction
5.2 Antibiotics
5.3 Acid Blockers
5.4 Corticosteroids
5.5 Decongestants
5.6 Combination Drug
5.7 Antihistamines
5.8 Other Drug Classes

6 Global Chronic Cough Market, By Route of Administration

6.1 Introduction
6.2 Inhalational
6.3 Oral
6.4 Injectable
6.5 Other Route of Administrations

7 Global Chronic Cough Market, By Distribution Channel

7.1 Introduction
7.2 Retail Pharmacy
7.3 Hospital Pharmacy
7.4 Online Pharmacy

8 Global Chronic Cough Market, By End User

8.1 Introduction
8.2 Speciality Centres
8.3 Homecare
8.4 Hospitals
8.5 Other End Users

9 Global Chronic Cough Market, By Geography

9.1 Introduction
9.2 North America
- 9.2.1 US
- 9.2.2 Canada
- 9.2.3 Mexico
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 Italy
- 9.3.4 France
- 9.3.5 Spain
- 9.3.6 Rest of Europe
9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 New Zealand
- 9.4.6 South Korea
- 9.4.7 Rest of Asia Pacific
9.5 South America
- 9.5.1 Argentina
- 9.5.2 Brazil
- 9.5.3 Chile
- 9.5.4 Rest of South America
9.6 Middle East & Africa
- 9.6.1 Saudi Arabia
- 9.6.2 UAE
- 9.6.3 Qatar
- 9.6.4 South Africa
- 9.6.5 Rest of Middle East & Africa

10 Key Developments

10.1 Agreements, Partnerships, Collaborations and Joint Ventures
10.2 Acquisitions & Mergers
10.3 New Product Launch
10.4 Expansions
10.5 Other Key Strategies

11 Company Profiling

11.1 Teva Pharmaceuticals Industries
11.2 Mylan N.V.
11.3 Amneal Pharmaceuticals LLC
11.4 Novartis AG
11.5 Hikma Pharmaceuticals Plc
11.6 Bayer AG
11.7 GSK plc
11.8 Aurobindo Pharma
11.9 Apotex Inc.
11.10 Micro Labs Ltd
11.11 AstraZeneca plc
11.12 Sun Pharmaceuticals Industries Ltd
11.13 Cipla Limited
11.14 Glenmark Pharmaceuticals Ltd
11.15 NeRRe Therapeutics
11.16 Pfizer Inc.

慢性咳嗽市場の2030年までの予測：薬剤クラス別、投与経路別、流通チャネル別、エンドユーザー別、地域別の世界分析

Chronic Cough Market Forecasts to 2030 - Global Analysis By Drug Class, Route of Administration, Distribution Channel, End User and By Geography

COVID-19の影響：

最大のシェアを占める地域

CAGRが最も高い地域：

無料のカスタマイズサービス：

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

目次

第1章 エグゼクティブサマリー

第2章 序文

第3章 市場動向分析

第4章 ポーターのファイブフォース分析

第5章 世界の慢性咳嗽市場：薬剤クラス別

第6章 世界の慢性咳嗽市場：投与経路別

第7章 世界の慢性咳嗽市場：流通チャネル別

第8章 世界の慢性咳嗽市場：エンドユーザー別

第9章 世界の慢性咳嗽市場：地域別

第10章 主な発展

第11章 企業プロファイル